Background Immune checkpoint blockade (ICB) has limited efficacy in microsatellite stable (MSS) colorectal cancer (CRC) due to an immunosuppressive tumour microenvironment. Although loss of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results